|Day Low/High||279.50 / 280.75|
|52 Wk Low/High||135.00 / 286.20|
Johnson & Johnson plans to spin out Actelion's research and development unit into a separate business.
The Dow Jones Industrial Average took almost 103 years to reach 10,000 in March 1999 and nearly 18 more years to reach 20,000.
CEO Alex Gorsky dishes on Monday's meeting with President Trump during Johnson & Johnson's conference call.
The Dow Jones Industrial Average held slight weekly gains on Friday afternoon even in a down day for Wall Street.
Stocks rise on Friday, putting the Dow Jones Industrial Average one step closer to the psychologically important 20,000 level.
U.S. stock futures are mixed while the dollar surges as global markets adjust to higher U.S. interest rates; Facebook plans to fact-check its news; Adobe's earnings top forecasts.
European stocks are set to book another solid weekly advance amid global market adjustments to the new Fed outlook.
Actelion stocks surged higher in Zurich amid speculation that France's Sanofi may make a formal approach for the Swiss biotech.
Actelion was too pricey. Now J&J is looking for another acquisition.
Shares in Europe's biggest biotech fall 9%, to a 25% discount to J&J's rumored bid, while Sanofi declines to comment on reports it is in talks.
The chances of the French drug company muscling in on Johnson & Johnson's talks with Actelion are slim, based on Sanofi's cost of capital vs. return from a possible deal.
U.S. stock futures point lower as crude oil gyrates after Saudi Arabia pulls out of a meeting Monday with Russia and other large non-OPEC producers.
Johnson & Johnson has some of the world's best-known health and personal care brands, while Actelion manufactures popular treatments for pulmonary arterial hypertension.
European markets closed higher for the third week running, led by Johnson & Johnson target Actelion, while oil contractors fell along with the price of Brent crude oil.
Wall Street hit new highs on Friday in a half-day session after the Thanksgiving holiday.
Stocks edge higher on Friday, on track to post another record session, in a quieter session after the Thanksgiving holiday in the U.S.
Stock futures edge higher on Friday, on track to post another record session, in a quieter session after the Thanksgiving holiday.
Target sees a surge in online traffic on Thanksgiving; U.S. stock futures suggest the Dow will open at another record high; J&J reportedly is bidding for Switzerland's Actelion.
European stocks fell in the first hour of trading amid a strong U.S. dollar and rising bond yields.
The Swiss biotech was last year reported to be a target of Shire.
Shares of ZS Pharma are surging after the development stage drugmaker agreed to be acquired by pharmaceutical giant AstraZeneca in a $2.7B deal.
There's plenty of action in European markets Monday, despite continued nervousness about negotiations with Greece and some downsizing of expectations on the British economy.
The CNBC 'Fast Money Halftime' traders dissect the anticipation of an interest rate hike, and say investors may be best off sticking with clear winners like health care stocks.
Shares of a number of biopharmaceutical companies are climbing after drug maker Roche agreed to buy its smaller peer, Intermune, developer of treatments for respiratory and orphan fibrotic diseases.
European stocks rebound Tuesday, as EU foreign ministers gather in Brussels to discuss whether to increase sanctions against Russia.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.